Semax Neuropeptide Research Guide 2026 — Molecular Profile, BDNF/TrkB Mechanism & Verification

Semax is a synthetic heptapeptide derived from the ACTH(4–10) fragment of adrenocorticotropic hormone, and it has become one of the most frequently referenced peptide tools in laboratories studying neurotrophin signaling. Because it engages the brain-derived neurotrophic factor (BDNF) / TrkB axis — a signaling system that sits at the center of neuronal survival, synaptic plasticity, and long-term potentiation research — Semax occupies an unusual place in the literature: a short, chemically simple peptide that produces a measurable, reproducible molecular readout in controlled preclinical systems. For research groups modeling neurotrophic transcription, cortical ischemia responses, and ACTH-derived peptide pharmacology, Semax connects a single well-characterized sequence to a receptor-and-transcription cascade that has been mapped in detail over three decades of published work.

This guide is written for qualified laboratory researchers sourcing Semax as a research compound. It covers the molecular profile, the mechanism at the pathway and transcriptional level as described in the published literature, representative preclinical research data, real citations you can verify yourself through PubMed and PubMed Central, in-vitro research applications, and how to evaluate the analytical documentation that should accompany a peptide of this class. It also situates Semax within the current U.S. regulatory context, which is directly relevant in July 2026.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

Semax is a compact, linear seven-residue peptide built on the ACTH(4–7) core sequence Met-Glu-His-Phe, extended at the C-terminus by a Pro-Gly-Pro tripeptide tail. That tail is the defining engineering feature of the molecule: it markedly increases resistance to enzymatic degradation relative to the unmodified ACTH fragment, which gives Semax a longer functional half-life in experimental systems while removing the classic steroidogenic activity of the parent hormone.

• Compound name: Semax
• CAS number: 80714-61-0
• Molecular formula: C₃₇H₅₁N₉O₁₀S
• Molecular weight: ≈ 813.9 g/mol
• Length: Linear heptapeptide (7 residues)
• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
• Parent fragment: ACTH(4–7) core plus a C-terminal Pro-Gly-Pro tail
• Appearance: White lyophilized powder; reconstituted in aqueous buffer for in-vitro work

Two structural details matter for sourcing. First, the single methionine residue at the N-terminus carries a thioether side chain that is susceptible to oxidation; a methionine-sulfoxide by-product shares nearly the same amino-acid composition as intact Semax but differs by 16 daltons in mass and shifts on reversed-phase chromatography. A competent COA should therefore confirm both mass and chromatographic purity so that oxidized material is resolved. Second, Semax is frequently confused at the catalog level with its N-acetylated analogue (N-acetyl Semax) and with the amidated variant; these are distinct molecules with distinct masses, and identity documentation should state precisely which species was supplied.

At roughly 814 g/mol, Semax sits at the small end of the peptide range, and its histidine and glutamate residues give it a distinctive, well-behaved fingerprint on LC-MS. A clean protonated-molecule signal near 814 Da, together with the expected multiply-charged ions, is the identity signature to look for, and the single free N-terminal methionine is the residue most worth watching for oxidation-related heterogeneity.

Section 2 — Mechanism (Pathway Language)

Semax is studied as a neurotrophin-pathway modulator. The published mechanistic literature describes it at the level of receptor signaling, gene transcription, and second-messenger cascades — not at the level of any clinical endpoint.

BDNF / TrkB axis. The most consistently reported molecular action of Semax is upregulation of brain-derived neurotrophic factor and its cognate receptor, tropomyosin receptor kinase B (TrkB). In controlled rodent-tissue systems, Semax has been studied for its capacity to raise BDNF messenger RNA and protein levels and to increase TrkB phosphorylation, the receptor-activation event that initiates downstream neurotrophic signaling.

Downstream signaling cascades. BDNF binding to TrkB is described in the literature as engaging three canonical intracellular pathways: the MAPK/ERK cascade, the PI3K/Akt cascade, and phospholipase C-gamma (PLC-γ) signaling. These are the same pathways studied in the broader neurotrophin field for their role in neuronal survival and synaptic plasticity, and they provide the measurable in-vitro readouts — phospho-ERK, phospho-Akt, CREB activation — used to quantify neurotrophic signaling in cell models.

CREB-dependent transcription. Semax has been studied for its capacity to drive BDNF transcription through the cAMP response element-binding protein (CREB), a transcription factor that links surface-receptor signaling to the expression of neurotrophin genes. This transcriptional layer is why much of the Semax literature is built on gene-expression and mRNA-quantification methods rather than binding assays alone.

ACTH derivation without steroidogenic activity. Because Semax retains the ACTH(4–7) melanocortin-adjacent core but lacks the residues responsible for adrenal steroidogenesis, it is studied as a neuroactive fragment distinct from the hypothalamic-pituitary-adrenal signaling of the parent hormone. This separation of neurotrophic from steroidogenic activity is a defining theme of the ACTH-fragment literature.

In accordance with research-context framing, this article describes Semax strictly at the receptor-signaling and transcriptional level. It is studied for its interaction with the BDNF/TrkB axis, downstream MAPK/PI3K/PLC-γ signaling, and CREB-dependent neurotrophin transcription in controlled systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical Research Data

The Semax literature is unusually deep for a peptide of this size, spanning receptor-binding studies, protein and mRNA quantification, and genome-wide transcriptional analysis.

Neurotrophin protein and mRNA induction. Foundational rodent-tissue work characterized Semax as an ACTH(4–10) analogue that raises BDNF and TrkB expression in the hippocampus. A single application (reported at 50 μg/kg in the source models) was associated with a maximal ~1.4-fold increase in BDNF protein, a ~1.6-fold increase in TrkB tyrosine phosphorylation, and roughly 3-fold and 2-fold increases in exon-III BDNF and TrkB mRNA, respectively. This established the neurotrophin-induction readout as the standard in-vitro and ex-vivo endpoint for the compound.

Specific binding in the basal forebrain. Companion work reported that Semax binds specifically in the rat basal forebrain and produces a rapid rise in BDNF protein within hours of administration, providing protein-level confirmation that complements the mRNA data. The specificity of this binding is part of what distinguishes Semax from non-specific peptide fragments in receptor-characterization studies.

Genome-wide transcriptional response. In cortical-ischemia models, genome-wide microarray analysis showed that Semax altered the expression of dozens of genes in ischemized rat cortex — reported as roughly 96 genes at 3 hours and 68 genes at 24 hours after permanent middle cerebral artery occlusion — with a predominant enhancement of immune-system and vascular-system gene programs. This transcriptomic work reframed Semax from a single-pathway neurotrophic probe into a broader modulator of the tissue-level response to ischemic stress in controlled animal models.

Across these studies, the recurring experimental thread is a measurable molecular endpoint — BDNF/TrkB protein levels, phosphorylation status, mRNA transcript counts, or genome-wide expression profiles — quantified in a defined cell-based or tissue system.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed and PubMed Central (PMC). Researchers are encouraged to read the primary sources directly.

• Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Research. 2006;1117(1):54–60 — foundational report of BDNF and TrkB mRNA/protein and phosphorylation changes in the hippocampus.
• Dolotov OV, Karpenko EA, Seredenina TS, et al. “Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry. 2006;97 Suppl 1:82–86 (doi:10.1111/j.1471-4159.2006.03658.x) — specific binding and protein-level BDNF confirmation.
• Shadrina M, Kolomin T, Agapova T, et al. “Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.” Cellular and Molecular Neurobiology. 2010. PubMed: 19633950 — neurotrophin and receptor gene transcription following ischemia.
• Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228. PMC: PMC3987924 — genome-wide microarray characterization of the Semax transcriptional response.
• Filippenkov IB, Stavchansky VV, Denisova AE, et al. “Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period.” Genes (Basel). 2023;14(7):1382 — later transcriptomic analysis of ACTH-derived peptides including Semax.
• “The Effect of Peptide Semax, an ACTH(4–10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.” Bulletin of Experimental Biology and Medicine. 2025 (doi:10.1007/s10517-025-06501-z) — recent work on calcium-signaling dynamics in neurons.

Citing real primary literature is a core part of the PYXAX research-context standard. Any source — vendor or publication — that references “studies” without traceable identifiers should be treated with caution. Because much of the Semax literature originates from a single research lineage in molecular genetics, the strongest evidentiary practice is to read the primary transcriptional and binding reports directly and to keep clear the distinction between preclinical mechanistic data and any downstream claims.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, Semax is used as a reference and probe compound in several categories of in-vitro and preclinical work:

• Neurotrophin signaling research — as a tool compound in BDNF/TrkB induction and receptor-phosphorylation assays.
• CREB-dependent transcription studies — as a stimulus in reporter and mRNA-quantification systems measuring neurotrophin gene expression.
• Downstream kinase-cascade research — as a probe in phospho-ERK, phospho-Akt, and PLC-γ signaling readouts in neuronal cell models.
• Ischemia-model transcriptomics — as a reference peptide in genome-wide expression studies of the cortical response to ischemic stress.
• ACTH-fragment structure–activity research — as a defined analogue for comparing neuroactive versus steroidogenic fragments of the parent hormone.
• Analytical method development — as a defined heptapeptide standard for validating reversed-phase HPLC and LC-MS identity methods, including resolution of methionine-oxidized by-products.

Each of these applications is an in-vitro or preclinical research use. Compounds supplied for research are not intended for, and must not be used in, any human or veterinary context.

Section 6 — How to Evaluate a Source

Semax is a small linear peptide with an oxidation-prone methionine and several closely related analogues in the market, which makes analytical documentation more — not less — important. The following steps separate verifiable sourcing from marketing claims.

Step 1 — Confirm the exact molecule and form. The COA and product page should state that the material is Semax (not N-acetyl Semax or an amidated variant), give the sequence Met-Glu-His-Phe-Pro-Gly-Pro, and report a molecular weight near 814 g/mol. Ambiguity between Semax and its acetylated analogue is a documentation gap, not a detail.

Step 2 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO 17025-accredited facility or equivalent recognized accreditation, and a COA that names the lab that tested the specific batch.

Step 3 — Confirm identity by mass spectrometry. A genuine Semax sample should present a protonated-molecule signal consistent with an ~814 g/mol heptapeptide on LC-MS. A COA that reports only “purity” without an identity mass is incomplete — and for a methionine-containing peptide, mass confirms whether oxidized species are present.

Step 4 — Confirm chromatographic purity and check for related peptides. HPLC should show a single dominant peak. The relevant impurities to resolve are methionine-sulfoxide oxidation products and any acetylated-analogue carry-over; a well-resolved reversed-phase method plus an accompanying mass spectrum will reveal them.

Step 5 — Verify lot specificity and a complete panel. The batch number on the COA must match the vial label and correspond to the production lot — not a single historical testing event applied across an entire catalog. A COA you can verify independently, through a QR-linked laboratory portal or a searchable community database, is the standard to hold. For sensitive cell-based signaling work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound neurotrophic-assay systems.

Section 7 — Regulatory Context (July 2026)

Researchers sourcing Semax in the United States should understand how it sits in the current landscape. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 at the FDA’s White Oak campus to consider a set of peptides for potential inclusion on the Section 503A Bulk Drug Substances List. Semax is on that docket, scheduled for review on July 24 alongside emideltide (DSIP) and epitalon, while BPC-157, KPV, TB-500, and MOTS-c are reviewed on July 23 — all in both free-base and acetate-salt forms. Ahead of the meeting, the FDA posted scientific briefing materials that, per industry reporting, lean toward not adding the substances to the 503A list, citing incomplete characterization and limited human safety and effectiveness data. PCAC recommendations are advisory only and are not final until the FDA issues its own determination. This compounding review concerns pharmacy compounding permissions; it does not constitute FDA approval of any peptide as a pharmaceutical drug, and it does not change the status of Semax as a compound supplied strictly for laboratory research. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX FDA peptide reclassification and peptide-compliance landscape guides for the full regulatory picture.)

Section 8 — PYXAX Verification Standard

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP <85> LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number. The batch number on the vial matches the batch number on the COA in the PYXAX COA Library, so researchers can confirm identity — including the exact sequence and form supplied — before ordering.

Community verification. Select lots are submitted to Janoshik Analytical for community verification, with results publicly searchable by batch number — no vendor contact required. Founding batches were verified through Krause Analytical (accredited US laboratory), and ongoing production lots are tested across the accredited-laboratory network described above, with a batch-specific COA published for every lot.

View PYXAX Semax →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/coa-library/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.